Age-related macular degeneration

Jun 30, 2022

LumiThera Announced the Result of US LIGHTSITE III Trial of Non-neovascular Age-Related Macular Degeneration (AMD) Subjects Treated with Photobiomodulation (PBM) using the Valeda® Light Delivery System On June 22, 2022, LumiThera Inc., a commercial-stage medical device company offering photobiomodulation (PBM) t...

May 27, 2022

The Dry AMD market is a billion-dollar business opportunity today as around 80–90% of individuals are affected by it. As per DelveInsight analysis, there were approximately 34.9 million cases of Dry AMD in 2021. Moreover, in 10–15% of patients with Dry AMD, the deterioration is more rapid and extensive, and they su...

Apr 18, 2022

 An Intraocular Lens implant is a synthetic, artificial lens placed inside the eye that replaces the focusing power of a natural lens that is surgically removed, usually as part of cataract surgery. Most Intraocular Lenses (IOL) are made of silicone, acrylic, or other plastic compositions and are also coated w...

Jun 16, 2021

The eyes are one of the most precious and delicate parts of the human body. Around 80% of the information from the surrounding environment that the human perceives comes from our eyes. The eyes require the best protection and care, as a slight disability can severely impact day-to-day activities and can also have l...

Apr 16, 2020

Vir's Hepatitis B drug shows positive results in phase 2 The hepatitis B drug of Vir Biotechnology has shown promising results. Its gene-silencing drug trim levels of the hepatitis B surface antigen in a small phase 2 study in patients who are already taking antiretroviral drugs. The drug, VIR-2218,...

Jan 16, 2018

UK based company conducting clinical trials on World's First Universal Flu Vaccine UK based company Vaccitech is currently conducting a clinical trial on a prospective drug that could serve as a universal flu vaccine in the world. Currently, there is no vaccine in the market that can be used for multiple flu probl...

Jan 15, 2018

Retinal Degeneration is the deterioration of the retina caused by the progressive and eventual death of the retinal cells. It is the damage to photoreceptor cells of the retina which malfunctions and distorts the received image. This is often a progressive disease in which the patient will suffer a continuous declin...

Jun 22, 2017

Novartis takes on Regeneron with AMD drug that needs fewer doses than Eylea Last year, U.S. sales of Regeneron’s drug to treat age-related macular degeneration (AMD) came in at $3.3 billion—68% of the company’s total revenues—so it’s no wonder investors have been expressing some concerns about potential rivals movin...